{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:29:21Z","timestamp":1793572161024,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"A2MCL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Increasing evidence supports the use of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation for diagnosis of dementia. However, their performance for positive and differential diagnosis of dementia with Lewy bodies (DLB) in clinical settings is still uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective biomarker study in two tertiary memory centers, Paris Lariboisi\u00e8re and CM2RR Strasbourg, France, enrolling patients with DLB (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009104), Alzheimer\u2019s disease (AD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200976), and neurological controls (NC,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927). Measured biomarkers included plasma A\u03b240\/A\u03b242 ratio, p-tau181, NfL, and GFAP using SIMOA and plasma YKL-40 and sTREM2 using ELISA. DLB patients with available CSF analysis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200990) were stratified according to their CSF A\u03b2 profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DLB patients displayed modified plasma A\u03b2 ratio, p-tau181, and GFAP levels compared with NC and modified plasma A\u03b2 ratio, p-tau181, GFAP, NfL, and sTREM2 levels compared with AD patients. Plasma p-tau181 best differentiated DLB from AD patients (ROC analysis, area under the curve [AUC]\u2009=\u20090.80) and NC (AUC\u2009=\u20090.78), and combining biomarkers did not improve diagnosis performance. Plasma p-tau181 was the best standalone biomarker to differentiate amyloid-positive from amyloid-negative DLB cases (AUC\u2009=\u20090.75) and was associated with cognitive status in the DLB group. Combining plasma A\u03b2 ratio, p-tau181 and NfL increased performance to identify amyloid copathology (AUC\u2009=\u20090.79). Principal component analysis identified different segregation patterns of biomarkers in the DLB and AD groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amyloid, tau, neurodegeneration and neuroinflammation plasma biomarkers are modified in DLB, albeit with moderate diagnosis performance. Plasma p-tau181 can contribute to identify A\u03b2 copathology in DLB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-024-01502-y","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:02:14Z","timestamp":1719975734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies"],"prefix":"10.1186","volume":"16","author":[{"given":"Agathe","family":"Vrillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bousiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Demuynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Ravier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Schorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Philippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hourregue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lilamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Cretin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"issue":"2","key":"1502_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JAD-190041","volume":"70","author":"M van de Beek","year":"2019","unstructured":"van de Beek M, van Steenoven I, Ramakers IHGB, Aalten P, Koek HL, Olde Rikkert MGM, et al. Trajectories and determinants of quality of life in dementia with Lewy Bodies and Alzheimer\u2019s Disease. J Alzheimers Dis. 2019;70(2):389\u201397.","journal-title":"J Alzheimers Dis"},{"key":"1502_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2019.01.005","volume":"50","author":"C Mueller","year":"2019","unstructured":"Mueller C, Soysal P, Rongve A, Isik AT, Thompson T, Maggi S, et al. Survival time and differences between dementia with Lewy bodies and Alzheimer\u2019s disease following diagnosis: a meta-analysis of longitudinal studies. Ageing Res Rev. 2019;50:72\u201380.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"1502_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40120-023-00467-8","volume":"12","author":"C Abdelnour","year":"2023","unstructured":"Abdelnour C, Gonzalez MC, Gibson LL, Poston KL, Ballard CG, Cummings JL, et al. Dementia with Lewy Bodies Drug Therapies in clinical trials: systematic review up to 2022. Neurol Ther. 2023;12(3):727\u201349.","journal-title":"Neurol Ther"},{"issue":"1","key":"1502_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"7","key":"1502_CR5","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"01","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;01(7):2181\u201393.","journal-title":"Brain"},{"issue":"5","key":"1502_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","volume":"129","author":"L Walker","year":"2015","unstructured":"Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, et al. Neuropathologically mixed Alzheimer\u2019s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129(5):729\u201348.","journal-title":"Acta Neuropathol"},{"key":"1502_CR7","doi-asserted-by":"publisher","first-page":"105698","DOI":"10.1016\/j.nbd.2022.105698","volume":"168","author":"J Amin","year":"2022","unstructured":"Amin J, Erskine D, Donaghy PC, Surendranathan A, Swann P, Kunicki AP, et al. Inflammation in dementia with Lewy bodies. Neurobiol Dis. 2022;168:105698.","journal-title":"Neurobiol Dis"},{"issue":"10","key":"1502_CR8","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/acn3.50897","volume":"6","author":"M Bongianni","year":"2019","unstructured":"Bongianni M, Ladogana A, Capaldi S, Klotz S, Baiardi S, Cagnin A, et al. \u03b1-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol. 2019;6(10):2120\u20136.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1502_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-022-01388-7","volume":"10","author":"S Hall","year":"2022","unstructured":"Hall S, Orr\u00f9 CD, Serrano GE, Galasko D, Hughson AG, Groveman BR, et al. Performance of \u03b1Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathol Commun. 2022;10(1):90.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1502_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga GM, Mammana A, Baiardi S, Rossi M, Ticca A, Magliocchetti F, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol. 2024;147(1):18.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1502_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno S, ichi, Imamichi-Tatano Y, et al. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med. 2023;29(6):1448\u201355.","journal-title":"Nat Med"},{"issue":"1","key":"1502_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","volume":"79","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, et al. Association of Plasma p-tau181 and p-tau231 concentrations with Cognitive decline in patients with probable dementia with Lewy Bodies. JAMA Neurol. 2022;79(1):32\u20137.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1502_CR13","doi-asserted-by":"publisher","first-page":"e1916439","DOI":"10.1001\/jamanetworkopen.2019.16439","volume":"2","author":"Z Nedelska","year":"2019","unstructured":"Nedelska Z, Schwarz CG, Lesnick TG, Boeve BF, Przybelski SA, Lowe VJ, et al. Association of Longitudinal \u03b2-Amyloid Accumulation determined by Positron Emission Tomography with Clinical and Cognitive decline in adults with probable Lewy Body Dementia. JAMA Netw Open. 2019;2(12):e1916439.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1502_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mds.28370","volume":"36","author":"S Hall","year":"2021","unstructured":"Hall S, Janelidze S, Londos E, Leuzy A, Stomrud E, Dage JL, et al. Plasma phospho-tau identifies Alzheimer\u2019s Co-pathology in patients with Lewy Body Disease. Mov Disord. 2021;36(3):767\u201371.","journal-title":"Mov Disord"},{"issue":"8","key":"1502_CR15","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti C, Palmqvist S, Hall S, Rossi M, Mammana A, Janelidze S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29(8):1964\u201370.","journal-title":"Nat Med"},{"issue":"5","key":"1502_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/acn3.51768","volume":"10","author":"KAQ Cousins","year":"2023","unstructured":"Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, et al. Plasma GFAP associates with secondary Alzheimer\u2019s pathology in Lewy body disease. Ann Clin Transl Neurol. 2023;10(5):802\u201313.","journal-title":"Ann Clin Transl Neurol"},{"key":"1502_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2022.07.008","volume":"101","author":"PC Donaghy","year":"2022","unstructured":"Donaghy PC, Firbank M, Petrides G, Lloyd J, Barnett N, Olsen K, et al. The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. Parkinsonism Relat Disord. 2022;101:111\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1502_CR18","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1038\/s41598-019-44173-8","volume":"24","author":"E Morenas-Rodr\u00edguez","year":"2019","unstructured":"Morenas-Rodr\u00edguez E, Alcolea D, Su\u00e1rez-Calvet M, Mu\u00f1oz-Llahuna L, Vilaplana E, Sala I, et al. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer\u2019s disease. Sci Rep. 2019;24(1):7803.","journal-title":"Sci Rep"},{"issue":"1","key":"1502_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","volume":"16","author":"A Villar-Piqu\u00e9","year":"2019","unstructured":"Villar-Piqu\u00e9 A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. 2019;16(1):145.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"1502_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1502_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1502_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00415-014-7335-6","volume":"261","author":"J Dumurgier","year":"2014","unstructured":"Dumurgier J, Laplanche JL, Mouton-Liger F, Lapalus P, Indart S, Pr\u00e9vot M, et al. The screening of Alzheimer\u2019s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. J Neurol. 2014;261(6):1187\u201395.","journal-title":"J Neurol"},{"issue":"4","key":"1502_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1502_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000365637","volume":"43","author":"V Philipps","year":"2014","unstructured":"Philipps V, Amieva H, Andrieu S, Dufouil C, Berr C, Dartigues JF, et al. Normalized Mini-mental State examination for assessing cognitive change in population-based brain aging studies. Neuroepidemiology. 2014;43(1):15\u201325.","journal-title":"Neuroepidemiology"},{"key":"1502_CR25","doi-asserted-by":"crossref","unstructured":"Hamilton CA, O\u2019Brien J, Heslegrave A, Laban R, Donaghy P, Durcan R et al. Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies. Psychol Med. 2023;1\u20139.","DOI":"10.1017\/S0033291723001952"},{"issue":"6","key":"1502_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93(6):651\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1502_CR27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78(12):1471\u201383.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1502_CR28","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/brain\/awy265","volume":"141","author":"A Surendranathan","year":"2018","unstructured":"Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R, et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain. 2018;141(12):3415\u201327.","journal-title":"Brain"},{"issue":"6","key":"1502_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/mds.27333","volume":"33","author":"D Erskine","year":"2018","unstructured":"Erskine D, Ding J, Thomas AJ, Kaganovich A, Khundakar AA, Hanson PS, et al. Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies. Mov Disord. 2018;33(6):982\u201391.","journal-title":"Mov Disord"},{"issue":"2","key":"1502_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bpa.12917","volume":"31","author":"CYB Low","year":"2021","unstructured":"Low CYB, Lee JH, Lim FTW, Lee C, Ballard C, Francis PT, et al. Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer\u2019s disease and Lewy body dementias. Brain Pathol. 2021;31(2):253\u201366.","journal-title":"Brain Pathol"},{"issue":"1","key":"1502_CR31","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.","journal-title":"Nat Commun"},{"issue":"1","key":"1502_CR32","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1212\/WNL.0000000000207371","volume":"101","author":"L Barba","year":"2023","unstructured":"Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, et al. CSF synaptic biomarkers in AT(N)-Based subgroups of Lewy Body Disease. Neurology. 2023;101(1):e50\u201362.","journal-title":"Neurology"},{"key":"1502_CR33","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.nbd.2022.105937","volume":"176","author":"K G\u00f6tze","year":"2023","unstructured":"G\u00f6tze K, Vrillon A, Bouaziz-Amar E, Mouton-Liger F, Hugon J, Martinet M, et al. Plasma neurofilament light chain in memory clinic practice: evidence from a real-life study. Neurobiol Dis. 2023;176:105937.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1502_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.bbrc.2018.03.226","volume":"499","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Feng S, Nie K, Li Y, Gao Y, Gan R, et al. TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson\u2019s disease. Biochem Biophys Res Commun. 2018;499(4):797\u2013802.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1502_CR35","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","volume":"22","author":"D Bonneh-Barkay","year":"2012","unstructured":"Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22(4):530\u201346.","journal-title":"Brain Pathol"},{"issue":"1","key":"1502_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13024-017-0197-5","volume":"12","author":"TR Jay","year":"2017","unstructured":"Jay TR, Von Saucken VE, Landreth GE. TREM2 in neurodegenerative diseases. Mol Neurodegeneration. 2017;12(1):56.","journal-title":"Mol Neurodegeneration"},{"issue":"11","key":"1502_CR37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/jnnp-2020-323603","volume":"91","author":"J Amin","year":"2020","unstructured":"Amin J, Boche D, Clough Z, Teeling J, Williams A, Gao Y, et al. Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer\u2019s disease: an observational clinical study. J Neurol Neurosurg Psychiatry. 2020;91(11):1219\u201326.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1502_CR38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2017-317134","volume":"89","author":"E King","year":"2018","unstructured":"King E, O\u2019Brien JT, Donaghy P, Morris C, Barnett N, Olsen K, et al. Peripheral inflammation in prodromal Alzheimer\u2019s and Lewy body dementias. J Neurol Neurosurg Psychiatry. 2018;89(4):339\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1502_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.25392","volume":"85","author":"D Coughlin","year":"2019","unstructured":"Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, et al. Cognitive and pathological influences of Tau Pathology in Lewy Body Disorders. Ann Neurol. 2019;85(2):259\u201371.","journal-title":"Ann Neurol"},{"key":"1502_CR40","doi-asserted-by":"crossref","unstructured":"Irwin J, Hurtig DI. H. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J Alzheimers Dis Parkinsonism [Internet]. 2018 [cited 2023 Oct 31];08(04). https:\/\/www.omicsonline.org\/open-access\/the-contribution-of-tau-amyloidbeta-and-alphasynuclein-pathology-todementia-in-lewy-body-disorders-2161-0460-1000444-103649.html.","DOI":"10.4172\/2161-0460.1000444"},{"issue":"3","key":"1502_CR41","doi-asserted-by":"publisher","first-page":"fcab180","DOI":"10.1093\/braincomms\/fcab180","volume":"3","author":"R Biundo","year":"2021","unstructured":"Biundo R, Weis L, Fiorenzato E, Pistonesi F, Cagnin A, Bertoldo A, et al. The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. Brain Commun. 2021;3(3):fcab180.","journal-title":"Brain Commun"},{"issue":"11","key":"1502_CR42","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144(11):3505\u201316.","journal-title":"Brain"},{"issue":"3","key":"1502_CR43","first-page":"792","volume":"140","author":"Z Fan","year":"2017","unstructured":"Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer\u2019s disease trajectory. Brain. 2017;140(3):792\u2013803.","journal-title":"Brain"},{"issue":"4","key":"1502_CR44","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3233\/JAD-170274","volume":"59","author":"R Skogseth","year":"2017","unstructured":"Skogseth R, Hortob\u00e1gyi T, Soennesyn H, Chwiszczuk L, Ffytche D, Rongve A, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies versus Neuropathology. J Alzheimers Dis. 2017;59(4):1139\u201352.","journal-title":"J Alzheimers Dis"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01502-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:06:12Z","timestamp":1719975972000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01502-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01502-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients or their legal relatives gave written informed consent to their participation in the study. For Paris cohort, the collection and analysis of samples were approved by the local ethic committee of Bichat University, Paris, France (CEERB GHU Nord n\u00b010\u2013037). For Strasbourg cohort, this study was part of the larger cohort study AlphaLewyMA (\n                      \n                      , registered June 11, 2013), approved by the ethics committee of East France (IV). All procedures were in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F.B. was the national coordinator for France for the Eisai Delphia (E2027), Axovant Headway-DLB and Roche Graduate therapeutic trials; he had received honoraria from Roche, Eisai and Biogen for oral presentations, and from Eisai for a board. C.P. is a member of the International Advisory Boards of Lilly; is a consultant for Fujiribio, Alzhois, Neuroimmune, Ads Neuroscience, Roche, AgenT and Gilead; and is involved as an investigator in several clinical trials for Roche, Esai, Lilly, Biogen, Astrazeneca, Lundbeck, and Neuroimmune. All other authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}